ARCT
Price
$21.92
Change
+$1.44 (+7.03%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
556.12M
34 days until earnings call
LRMR
Price
$4.28
Change
+$0.13 (+3.13%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
355.2M
47 days until earnings call
Interact to see
Advertisement

ARCT vs LRMR

Header iconARCT vs LRMR Comparison
Open Charts ARCT vs LRMRBanner chart's image
Arcturus Therapeutics Holdings
Price$21.92
Change+$1.44 (+7.03%)
Volume$7.56K
Capitalization556.12M
Larimar Therapeutics
Price$4.28
Change+$0.13 (+3.13%)
Volume$43.89K
Capitalization355.2M
ARCT vs LRMR Comparison Chart in %
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. LRMR commentary
Oct 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Hold and LRMR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 03, 2025
Stock price -- (ARCT: $20.48 vs. LRMR: $4.15)
Brand notoriety: ARCT and LRMR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 169% vs. LRMR: 515%
Market capitalization -- ARCT: $594.14M vs. LRMR: $366.33M
ARCT [@Biotechnology] is valued at $594.14M. LRMR’s [@Biotechnology] market capitalization is $366.33M. The market cap for tickers in the [@Biotechnology] industry ranges from $104.83B to $0. The average market capitalization across the [@Biotechnology] industry is $1.98B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileLRMR’s FA Score has 1 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • LRMR’s FA Score: 1 green, 4 red.
According to our system of comparison, ARCT is a better buy in the long-term than LRMR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 3 TA indicator(s) are bullish while LRMR’s TA Score has 6 bullish TA indicator(s).

  • ARCT’s TA Score: 3 bullish, 5 bearish.
  • LRMR’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, LRMR is a better buy in the short-term than ARCT.

Price Growth

ARCT (@Biotechnology) experienced а +1.09% price change this week, while LRMR (@Biotechnology) price change was -18.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.18%. For the same industry, the average monthly price growth was +13.86%, and the average quarterly price growth was +79.28%.

Reported Earning Dates

ARCT is expected to report earnings on Nov 05, 2025.

LRMR is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+5.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARCT($556M) has a higher market cap than LRMR($355M). ARCT YTD gains are higher at: 20.684 vs. LRMR (7.235). ARCT has higher annual earnings (EBITDA): -54.54M vs. LRMR (-108.21M). ARCT has more cash in the bank: 196M vs. LRMR (139M). LRMR has less debt than ARCT: LRMR (4.61M) vs ARCT (27M). ARCT has higher revenues than LRMR: ARCT (110M) vs LRMR (0).
ARCTLRMRARCT / LRMR
Capitalization556M355M157%
EBITDA-54.54M-108.21M50%
Gain YTD20.6847.235286%
P/E RatioN/AN/A-
Revenue110M0-
Total Cash196M139M141%
Total Debt27M4.61M585%
FUNDAMENTALS RATINGS
ARCT vs LRMR: Fundamental Ratings
ARCT
LRMR
OUTLOOK RATING
1..100
1713
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
29
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
4156
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
3750

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LRMR's Valuation (29) in the null industry is in the same range as ARCT (43) in the Pharmaceuticals Major industry. This means that LRMR’s stock grew similarly to ARCT’s over the last 12 months.

LRMR's Profit vs Risk Rating (100) in the null industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that LRMR’s stock grew similarly to ARCT’s over the last 12 months.

ARCT's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as LRMR (100) in the null industry. This means that ARCT’s stock grew similarly to LRMR’s over the last 12 months.

ARCT's Price Growth Rating (41) in the Pharmaceuticals Major industry is in the same range as LRMR (56) in the null industry. This means that ARCT’s stock grew similarly to LRMR’s over the last 12 months.

ARCT's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as LRMR (100) in the null industry. This means that ARCT’s stock grew similarly to LRMR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTLRMR
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 11 days ago
80%
Bullish Trend 15 days ago
85%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PUBC0.05N/A
+5.88%
Purebase Corporation
KYKOF17.13N/A
N/A
Kyowa Hakko Kogyo Co., Ltd.
KITAF0.97N/A
N/A
Kitanotatsujin Corporation
LNDAF1.58N/A
N/A
LINEA DIRECTA ASEGURADORA SA
UNCFF76.96-0.03
-0.03%
UniCredito Spa

LRMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, LRMR has been loosely correlated with ERAS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if LRMR jumps, then ERAS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LRMR
1D Price
Change %
LRMR100%
+28.48%
ERAS - LRMR
46%
Loosely correlated
+1.38%
MLTX - LRMR
46%
Loosely correlated
-1.53%
ARCT - LRMR
45%
Loosely correlated
+11.12%
TERN - LRMR
44%
Loosely correlated
+3.99%
OCUL - LRMR
44%
Loosely correlated
-5.56%
More